Therapeutics News

Researchers compiled a treatment algorithm for cutaneous manifestations of lupus erythematosus based on data from 104 studies, according to a study presented at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting.

Researchers suggested there is a dose relationship between smoking exposure and cutaneous manifestations in systemic lupus erythematosus, which highlights the importance of smoking cessation to improve outcomes, according to a presentation at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting.

CHICAGO — In patients with advanced cutaneous squamous cell carcinoma, a multidisciplinary discussion on treatment options should include oncologists, radiation oncologists and the primary care physician in weighing risks and benefits to various approaches, according to Todd Schlesinger, MD, FAAD, FASMS, medical director at Dermatology and Laser Center of Charleston.

CHICAGO — Fractional CO2 laser treatment was associated with improved signs and symptoms of vulvar lichen sclerosus, according to data from a pilot study presented at the American Society for Dermatologic Surgery annual meeting.

CHICAGO — Nano-pulse stimulation was associated with a reduction in cutaneous, nongenital wart size, according to data from a multicenter study presented at the American Society for Dermatologic Surgery annual meeting.

Bermekimab, which neutralizes interleukin-1 alpha, improved all disease measures of atopic dermatitis, including a large reduction in pruritus, according to phase 2 trial results presented at the European Academy of Dermatology and Venereology Congress by Alice Gottlieb, MD, PhD, of Icahn School of Medicine at Mount Sinai.

Patients with moderate to severe alopecia areata who were assigned to CTP-543, an oral Janus kinase inhibitor from Concert Pharmaceuticals, achieved a 50% relative reduction in Severity of Alopecia Tool score at 24 weeks, according to data presented at the European Academy of Dermatology and Venereology Congress.

by Deanne Mraz Robinson, MD

The safety and efficacy of Ilumya were maintained after 4 years of treatment among patients with plaque psoriasis enrolled in the open-label reSURFACE1 trial, according to data presented at the European Academy of Dermatology and Venereology Congress.

Adalimumab and phototherapy for psoriasis are both associated with statistically significant improvements in patient-reported outcomes after 12 weeks, but phototherapy yields greater improvement in quality of life and pain, according to recent study findings.